Creative Planning’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-100
Closed -$1K – 2226
2020
Q2
$1K Buy
+100
New +$11.1K ﹤0.01% 1996

Other funds holding NBIX

Creative Planning's NBIX Position: Q3 2026 in Review

Creative Planning increased its Neurocrine Biosciences (NBIX) stake by 0.41% in Q3 2026, buying an estimated $50.8K and bringing the position to 77,134 shares worth $10.9M. The position accounts for 0.01% of the portfolio, ranked #908.

Creative Planning first reported a position in NBIX in Q2 2013 and has held it in 51 quarters since. The position peaked at $12.9M in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Creative Planning held 77,134 shares of Neurocrine Biosciences worth $10.9M as of Q3 2026.
  • Creative Planning bought 316 Neurocrine Biosciences shares in Q3 2026, an estimated $50.8K.
  • Neurocrine Biosciences made up 0.01% of Creative Planning's portfolio in Q3 2026, its #908 holding.
  • Creative Planning first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 51 quarters since.
  • Creative Planning's Neurocrine Biosciences position peaked at $12.9M in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.